You are here: Industry Insights > Market News > Japan’s cabinet approves plan for free COVID-19 vaccines

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Japan’s cabinet approves plan for free COVID-19 vaccines

expresspharmaOctober 29, 2020

Tag: Japan , COVID-19 Vaccine , coronavirus

Favorites

Japan’s cabinet approved a plan on Tuesday to use public funds to provide novel coronavirus vaccines to the public for free.

The plan also calls for the government to bear the cost of any health damage caused by a vaccine, according to a document posted on the health ministry’s website.

Prime Minister Yoshihide Suga has pledged to provide enough vaccines for the coronavirus for the public by mid-2021.

Japan has struck deals for hundreds of millions of doses from companies including AstraZeneca and Pfizer.

Previous:Russia applies for WHO emergency use tag for its COVID-19 vaccine

Next:PMI announces Medicago to supply up to 76 mn doses of its plant-derived COVID-19 vaccine candidate

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

PharmaSourcesMay 21, 2024

The first patient has been dosed in a clinical trial of the Company's BCL2 inhibitor, ICP-248, in combination with orelabrutinib as a first-line therapy for chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL) in China.

Selection of Commercial Models for Innovative Drugs

PharmaSourcesMay 21, 2024

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

Biotech NewswireMay 17, 2024

Japan’s cabinet approves plan for free COVID-19 vaccines | Pharmasources.com

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

PharmaSourcesMay 16, 2024

InnoCare announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.

Japan’s cabinet approves plan for free COVID-19 vaccines

Related News

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Selection of Commercial Models for Innovative Drugs

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

You may like